Latest news and press releases about KalVista Pharmaceuticals, Inc. (KALV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Price
| Price | $27.00 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -503.31 |
| EV / EBITDA | -12.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1057.44% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -41.28% |
| Gross Margin | 92.03% |
| Operating Margin | -120.80% |
| Net Margin | -119.44% |
Related companies: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explore sector: Healthcare · Biotechnology
More sections of KALV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks